Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06506422 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Empagliflozin Reversal of Arterial StiffnEss in Aging

Study acronym: ERASE-Aging
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv7
  2. Eligibility criteria revisedv6
  3. Eligibility criteria shortened, about 1 wordv5
  4. Eligibility criteria expanded, about 66 wordsv4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v3
  6. Study description expanded, about 1 wordv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.
Trial Details
NCT Number NCT06506422
Lead Sponsor University of Missouri-Columbia
Conditions
(from sponsor)		 Aging, Arterial Stiffness
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov